ChemoCentryx and Forest develop new CCR1 compounds; deal ends
Chemokine-based drug discovery company ChemoCentryx and Forest Laboratories have entered into an agreement to develop and sell small-molecule compounds to treat autoimmune and inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
- Specialty Pharmaceuticals
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.